This module uses fundamental data of Eastwood Bio-Medical to approximate its Piotroski F score. Eastwood Bio-Medical F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Eastwood Bio Medical Canada. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Eastwood Bio-Medical financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eastwood Bio Medical Canada. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Eastwood
Piotroski F Score
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Average Inventory
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change To Inventory
Investments
Change In Cash
Net Borrowings
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Other Non Cash Items
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Depreciation
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Current Deferred Revenue
Net Debt
Retained Earnings
Accounts Payable
Cash
Cash And Short Term Investments
Net Receivables
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Other Current Assets
Total Liab
Total Current Assets
Common Stock
Non Current Assets Total
Non Currrent Assets Other
Net Invested Capital
Net Working Capital
Property Plant And Equipment Net
Short Term Debt
Property Plant Equipment
Other Assets
Short Long Term Debt Total
Long Term Debt
Property Plant And Equipment Gross
Interest Expense
Selling General Administrative
Selling And Marketing Expenses
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Depreciation And Amortization
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
At this time, Eastwood Bio-Medical's Net Debt is fairly stable compared to the past year. Short and Long Term Debt Total is likely to climb to about 38.5 K in 2024, whereas Long Term Debt is likely to drop slightly above 32.7 K in 2024. At this time, Eastwood Bio-Medical's Days Sales Outstanding is fairly stable compared to the past year. Average Payables is likely to climb to about 76.6 K in 2024, despite the fact that PTB Ratio is likely to grow to (206.81).
At this time, it appears that Eastwood Bio-Medical's Piotroski F Score is Inapplicable. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to Eastwood Bio-Medical is to make sure Eastwood is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Eastwood Bio-Medical's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Eastwood Bio-Medical's financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Eastwood Bio-Medical's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Eastwood Bio-Medical in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
(0.0133)
At this time, Eastwood Bio-Medical's Book Value Per Share is fairly stable compared to the past year.
Eastwood Bio-Medical Current Valuation Drivers
We derive many important indicators used in calculating different scores of Eastwood Bio-Medical from analyzing Eastwood Bio-Medical's financial statements. These drivers represent accounts that assess Eastwood Bio-Medical's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Eastwood Bio-Medical's important valuation drivers and their relationship over time.
The Macroaxis Fundamental Analysis modules help investors analyze Eastwood Bio Medical Canada's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eastwood Bio-Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eastwood Bio Medical Canada based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
When running Eastwood Bio-Medical's price analysis, check to measure Eastwood Bio-Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eastwood Bio-Medical is operating at the current time. Most of Eastwood Bio-Medical's value examination focuses on studying past and present price action to predict the probability of Eastwood Bio-Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eastwood Bio-Medical's price. Additionally, you may evaluate how the addition of Eastwood Bio-Medical to your portfolios can decrease your overall portfolio volatility.